TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15162946
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids (Beclomethasone) plus prolonged action bronchodilator (Salmeterol)
Study: 15162946
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids (Beclomethasone)
Study: 11458057
Drug: Polyestradiol phosphate
Normalized name: POLYESTRADIOL PHOSPHATE
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyestradiol phosphate (240 mg intramuscular injections every 2 weeks for 8 weeks, then monthly)
Study: 11458057
Drug: Complete androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete androgen ablation (bilateral orchiectomy or 3.75 mg triptorelin monthly with 250 mg flutamide 3 times daily)
Study: 10089183
Drug: Warfarin (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted to achieve an INR of 2.0 to 3.0)
Study: 1100014
Drug: 5,000 international
Normalized name: Nature Made Beta Carotene 25,000 International Units Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 international units aqueous heparin sodium
Study: 21628010
Drug: Various endoscopic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various endoscopic technologies (e.g., colonoscopy, third eye retroscope, cap-fitted, cap-assisted)
Study: 18993031
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to other medications from olanzapine
Study: 18993031
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to other medications from risperidone
Study: 16550824
Drug: Prostamol Uno
Normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostamol Uno 320 mg
Study: 12856138
Drug: Controlled ileal-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ileal-release budesonide (9 mg by mouth)
Study: 7687421
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with hyperthermia (HCR)
Study: 7687421
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Group A)
Study: 22532945
Drug: Breezy candy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breezy candy (sugar-free) containing zinc gluconate 0.5%, propolis 2%, and a combination of both (zinc 0.25% and propolis 1%)
Study: 31483938
Drug: Tinnitus Multivariate
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus Multivariate Integrated Sound Therapy (T-MIST)
Study: 26498242
Drug: Rilmazafone 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmazafone 1 mg
Study: 21864613
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator (licensed Td vaccine)
Study: 9400950
Drug: CDDP/VNR (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP/VNR (Cisplatin 100 mg m-2 on day 1 + Vinorelbine 25 mg m-2 i.v. on days 1 and 8 every 21 days for three cycles)
Study: 9400950
Drug: IFO/EPI (Ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFO/EPI (Ifosfamide 2.5 g m-2 with mesna on day 1 + High-dose Epirubicin 100 mg m-2 on day 1 every 21 days for three cycles)
Study: 8423870
Drug: Intranasal DGAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DGAVP treatment
Study: 2881482
Drug: Soy polysaccharide
Normalized name: Soy polysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy polysaccharide (10 g)
Study: 24093504
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (200/25 μg)
Study: 24093504
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (800/100 μg)
Study: 23084328
Drug: Minor drug
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor drug onset sensations
Study: 8907095
Drug: Group behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group behavioral treatment
Study: 8907095
Drug: Minimal contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal contact plus 2 mg of nicotine gum
Study: 6136395
Drug: Sulfasalazine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (2.0 g/day)
Study: 30639089
Drug: Postoperative bladder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative bladder backfilling with 150 mL of normal saline
Study: 26156227
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (2 ml Tissucol®; Duploject, Baxter AG) applied on surgical wound before closure
Study: 23870813
Drug: Discontinuous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous treatment
Study: 12908891
Drug: Increased ALNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased ALNA intake (10 g/d, n 4)
Study: 12908891
Drug: Increased EPA+DHA
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased EPA+DHA intake (1.5 g/d, n 5)
Study: 1875415
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 doxorubicin
Study: 1875415
Drug: 320 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg/m2 bisantrene
Study: 1875415
Drug: 14 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg/m2 mitoxantrone
Study: 6871069
Drug: Terbutaline sulphate
Normalized name: Terbutaline sulphate
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline sulphate (1 mg)
Study: 18715665
Drug: Interferon alfa-based
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-based antiviral therapies or treatment with polymerase inhibitors
Study: 18715665
Drug: Initial viral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR)
Study: 14669615
Drug: prestarium (2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: prestarium (2‐4 mg/day)
Study: 14669615
Drug: standard combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard combined therapy
Study: 11071181
Drug: suplatast tosilate
Normalized name: Edoxaban Tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: suplatast tosilate (100 mg three times daily)
Study: 9011485
Drug: Levothyroxine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (1.5 micrograms/kg daily)
Study: 9011485
Drug: Iodine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine (300 micrograms daily)
Study: 1735253
Drug: Budesonide 600
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 600 micrograms twice daily
Study: 6321684
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (TMP/SMZ) 320/1600 mg/day
Study: 30396226
Drug: Routine aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine aspirin 75 mg
Study: 30571234
Drug: Fetal Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal Medicine Foundation screen-and-treat approach
Study: 24102322
Drug: Sumatriptan 85
Normalized name: sumatriptan 85 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 85 mg/Naproxen sodium 500 mg (S/NS)
Study: 22318095
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg a day for 2 years
Study: 11720459
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and best supportive care (BSC)
Study: 8083129
Drug: Preoperative irradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative irradiation (single 7-8 Gy fraction administered < 4 h before surgery)
Study: 8083129
Drug: Postoperative irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative irradiation (single 7-8 Gy fraction administered < 48 h after surgery)
Study: 2521644
Drug: imipramine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine 200 mg/day for 3 weeks
Study: 1147583
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g every 6 h for 48 h
Study: 1147583
Drug: Cephalothin 2
Normalized name: cephalothin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin 2 g every 6 h for 48 h
Study: 15174779
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (supplement without zinc)
Study: 2929526
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral obesity treatment
Study: 30903287
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol 200 μg
Study: 30903287
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol 100 μg
Study: 30073445
Drug: Mobile app
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app for drug administration
Study: 28363526
Drug: Ceftazidime/avibactam (2000/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime/avibactam (2000/500 mg, 2-h infusion) plus metronidazole (500 mg, 60-min infusion)
Study: 28363526
Drug: Meropenem (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1000 mg, 30-min infusion)
Study: 21718775
Drug: Portulaca oleracea
Normalized name: Portulaca Oleracea Top
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portulaca oleracea (PO) seeds, 5 g twice daily
Study: 21718775
Drug: Metformin, 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 1,500 mg/day
Study: 18640386
Drug: Oral ERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ERT
Study: 18640386
Drug: Transdermal ERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal ERT
Study: 16595206
Drug: DMPA-SC (104
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA-SC (104 mg)
Study: 16595206
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (11.25 mg)
Study: 12874697
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg intravenous infusion)
Study: 9428817
Drug: Daclizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1.0 mg/kg body weight, administered intravenously before transplantation and once every other week afterward for a total of five doses)
Study: 9428817
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered intravenously before transplantation and once every other week afterward for a total of five doses)
Study: 2501243
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus mitomycin C
Study: 831472
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Study: 831472
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of heparin 1,000 units to each liter of intravenous fluid
Study: 831472
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of heparin 500 units and hydrocortisone phosphate 1 mg to each liter of intravenous fluid
Study: 831472
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of heparin 1,000 units and hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Study: 831472
Drug: Filtration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtration of intravenous solutions through a 0.22‐mum inline filter
Study: 31694152
Drug: Mixed flavonoid-caffeine
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed flavonoid-caffeine (MFC) supplement (658 mg flavonoids, 214 mg caffeine)
Study: 31694152
Drug: Mixed flavonoid-caffeine
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed flavonoid-caffeine (MFC) supplement
Study: 25936297
Drug: 0.1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g/kg l‐methionine to induce hyperhomocysteinemia
Study: 25936297
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml whipping cream (30% fat) to induce hyperlipidemia
Study: 18800037
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil administered for up to 7 days
Study: 16490627
Drug: Ramipril, 2.5
Normalized name: Ramipril, 2.5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril, 2.5 mg 3 times/wk
Study: 15256981
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment followed by Helicobacter pylori test and treat strategy (treat and test group)
Study: 8342399
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (4 micrograms/kg loading dose followed by 1 microgram/kg/h infusion)
Study: 27639819
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 0.5 mg/kg, twice daily (max 60 mg/day) from day one until discharge
Study: 20214176
Drug: Topical hemostatic
Normalized name: ferric sulfate 21 % Topical Hemostatic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hemostatic powder (THP)
Study: 12496983
Drug: Periprostatic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic injection of 5 ml 1% lidocaine solution (2.5 ml bilaterally)
Study: 9156938
Drug: HIV-negative drug
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-negative drug addicts (1986-87)
Study: 9156938
Drug: HIV-positive drug
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-positive drug addicts
Study: 1859008
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg‐1 bolus followed by infusion of 160 microgram.kg‐1.min‐1
Study: 6344981
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and high-dose methotrexate
Study: 28925135
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii glycosides (20 mg, tid for 4 weeks, then 10 mg, tid) combined with gestrinone (2.5 mg on 1st and 4th day of menstrual cycle, then twice a week)
Study: 28925135
Drug: Gestrinone capsule
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone capsule (same intake method as treatment group)
Study: 9492127
Drug: Injection within
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection within the wound (0.5 mL buffered lidocaine)
Study: 9492127
Drug: Injection through
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection through intact skin (0.5 mL buffered lidocaine)
Study: 9492127
Drug: First injection
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First injection (within wound) in group 1
Study: 9492127
Drug: Second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second injection (intact skin) in group 1
Study: 9492127
Drug: First injection
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First injection (intact skin) in group 2
Study: 9492127
Drug: Second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second injection (within wound) in group 2
Study: 8113006
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol (0.25%)
Study: 3381775
Drug: Half-strength formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-strength formula (equal parts, 84 J/30 mL [20 cal/oz] formula and water)
Study: 3381775
Drug: Full-strength (FS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength (FS) formula (84 J/30 mL [20 cal/oz])
Study: 11878727
Drug: GA, paracetamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural bupivacaine (Bupi)
Study: 11878727
Drug: GA, paracetamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural saline (Saline)
Study: 11878727
Drug: GA, paracetamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA, paracetamol, NSAID (GA)
Study: 3138609
Drug: Low-dose animal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose animal antigen injection
Study: 28973650
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% bupivacaine with 150 μg clonidine (clonidine group, n = 116)
Study: 28973650
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% bupivacaine alone (control group, n = 109)
Study: 26519614
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction plus treatment as usual
Study: 24480956
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of ramosetron
Study: 24480956
Drug: 0.075 mg
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg of palonosetron
Study: 21149771
Drug: 2-hour daily
Normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour daily patching of the sound eye
Study: 21149771
Drug: 5 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 sessions of acupuncture weekly
Study: 8540115
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) + transrectal ultrasonography (TRUS)
Study: 24695721
Drug: Baclofen (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (60 mg/d; 20 mg t.i.d.)
Study: 17992118
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy (arm A: trofosfamide 50 mg orally three times daily, day 1+)
Study: 17992118
Drug: Combined anti-inflammatory/angiostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anti-inflammatory/angiostatic treatment (arm B: trofosfamide as above plus rofecoxib 25 mg orally, day 1+, and pioglitazone 60 mg orally, day 1+)
Study: 17992118
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy (arm A)
Study: 17992118
Drug: Combined anti-inflammatory/angiostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anti-inflammatory/angiostatic treatment (arm B)
Study: 15224207
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of rosiglitazone (4 mg b.i.d.) to gliclazide (160 mg/day)
Study: 15224207
Drug: Uptitration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitration of gliclazide to a maximum of 320 mg/day
Study: 11786526
Drug: LY333531 (protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY333531 (protein kinase Cbeta inhibitor)
Study: 390528
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of atenolol daily
Study: 390528
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of atenolol daily
Study: 390528
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of atenolol daily (control)
Study: 6121762
Drug: Atenolol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (various doses)
Study: 390528
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 mg daily)
Study: 30201237
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus ketamine (0.1 mg/kg morphine plus 0.2 mg/kg ketamine)
Study: 30201237
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus placebo (0.1 mg/kg morphine plus normal saline)
Study: 23872799
Drug: IV pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pamidronate (1 mg/kg)
Study: 21769048
Drug: Citicoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (500 mg twice daily)
Study: 19254614
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all 3 devices
Study: 12062893
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg paroxetine
Study: 2492744
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (74 mumol.kg‐1.d‐1) during 11 postoperative days
Study: 982547
Drug: Suramin (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin (4-6 g)
Study: 11561266
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of mepivacaine (Group I)
Study: 11561266
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of mepivacaine (Group II)
Study: 11561266
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL twice with an interval of 5 minutes (Group III)
Study: 11561266
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL twice with an interval of 10 minutes (Group IV)
Study: 30667591
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release tacrolimus tablets (LCPT) 0.07-0.13 mg/kg/day